SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

  title={SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness},
  author={Aziz Sheikh and Jim McMenamin and Bob Taylor and Chris Robertson},
  journal={Lancet (London, England)},
  pages={2461 - 2462}
SARS-COV-2 Variants: Differences and Potential of Immune Evasion
This review addressed the following critical points concerning VOCs: characteristics of the SARS-CoV-2 V OCs with mutations in the S gene, possible evasion of variants from neutralizing antibodies generated through vaccination, previous infection, or immune therapies, potential risk of new pandemic waves induced by the variants worldwide, and perspectives for further studies and actions.
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
This study suggests that two dose regimes of vaccine are required for maximal BNT162b2 and ChAdOx1-induced immunity and demonstrates the quantifiable risk of antigenic drift and subsequent reduction in vaccine efficacy.
SARS-CoV-2 Variants of Concern
The molecular features, epidemiology, impact on transmissibility, disease severity, and vaccine effectiveness of VOCs are reviewed.
Epidemiology and Vaccine Efficacy of Delta Variant
With the emergence of new variants of SARS-CoV-2 due to continuous mutations, it is suggested that vaccination plays a significant role in preventing the transmission of disease and disease severity.
Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals
The data indicate that the Delta variant is associated with increased infectious virus loads when compared to the Alpha variant and decreased upper respiratory antiviral IgG levels.
Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021
PCR results from SARS-CoV-2-positive patients tested in the community in France from 14 June to 30 July 2021 showed that infections with the Delta variant had lower Cq values at symptom onset than with Alpha.
Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals
Analysis of SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021 finds evidence for an increased risk of infection by the Beta, Gamma or Delta variants relative to Alpha variant after vaccination.
Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins
Sera from vaccinated individuals had higher antibody levels and more efficiently inhibited the spike–ACE-2 interactions, even among individuals aged 18–49 years, showing the effectiveness of vaccination.


Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
After 2 doses of either vaccine there were only modest differences in vaccine effectiveness with the B.1.
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease.
Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data
This work aims to repurpose and expand an existing pandemic reporting platform to determine the attack rate of SARS-CoV-2, the uptake and effectiveness of any new pandemic vaccine (once available) and any protective effect conferred by existing or new antimicrobial drugs and other therapies.
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
A first dose of ChAdOx1 was found to be associated with small increased risks of ITP, with suggestive evidence of an increased risk of arterial thromboembolic and hemorrhagic events.
Cohort profile: Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database
Cohort profile: Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database Rachel H. Mulholland , Eleftheria Vasileiou,* Colin R. Simpson, Chris Robertson, Lewis D. Ritchie,
First dose ChAdOx 1 and BNT 162 b 2 COVID - 19 vaccines and thrombocytopenic , thromboembolic and haemorrhagic events in Scotland